Skip to main content
Log in

The Missing Link in the Diagnostic Pathway of Prostate Cancer

  • Short Communication
  • Published:
Pathology & Oncology Research

Abstract

Prostate cancer is one of the most common cancers in the Western world. It is among the leading causes of cancer related death. While its incidence and survival increased significantly during the last few decades in Denmark, the mortality rate did not change for patients younger than 80 year old. Development of new techniques, such as multiparametric MRI, helps to increase the accuracy of diagnosis. However, a missing link in the diagnostic pathway may result in mistreatment if an acinar adenocarcinoma of prostate is transformed into a neuroendocrine phenotype such as small cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Cookson MS, Roth BJ, Dahm P, et al. (2015) Castration-Resistant Prostate Cancer. AUA Guideline. In AUA Guidelines https://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm. Accessed 27 June 2016

  2. Mottet N, Bellmunt J, Briers E, et al. (2016) Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/. Accessed 27 June 2016

  3. Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 34:22–29

    Article  CAS  PubMed  Google Scholar 

  4. Spiess PE, Pettaway CA, Vakar-Lopez F et al (2007) Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110:1729–1737

    Article  PubMed  Google Scholar 

  5. Li Z, Sun Y, Chen X et al (2015) P 53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res 13:584–591

    Article  CAS  PubMed  Google Scholar 

  6. Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60

    Article  PubMed  PubMed Central  Google Scholar 

  7. Burchardt T, Burchardt M, Chen MW et al (1999) Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162:1800–1805

    Article  CAS  PubMed  Google Scholar 

  8. Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637

    CAS  PubMed  Google Scholar 

  9. Vlachostergios PJ, Papandreou CN (2015) Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 5:6

    Article  PubMed  PubMed Central  Google Scholar 

  10. Small EJ, Huang J, Youngren J, et al. (2015) Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). 2015 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/152182-156. Accessed 27 June 2016

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Laszlo Hegyi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wøyen, A.V.T., Laczkó, G., Høyer, S. et al. The Missing Link in the Diagnostic Pathway of Prostate Cancer. Pathol. Oncol. Res. 23, 447–450 (2017). https://doi.org/10.1007/s12253-016-0183-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0183-1

Keywords

Navigation